0000000000937360
AUTHOR
Laurent Beaugerie
Additional file 6 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 6. (A) Sorensen similarity index between donor and recipient fecal microbiota 6 weeks after FMT or sham, separating “FMT” failure from “FMT success”.
Additional file 10 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 10. Clinical efficacy of FMT is associated with colonization by the donor microbiota. Flare-free survival of patients in the FMT and the Sham groups.
Additional file 9 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 9. Evolution of similarity index (1-unweighted Unifrac) between donor and recipient fecal microbiota in patients with FMT success and FMT failure.
Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6…
Additional file 2 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 2. Screening measures for donors.
Additional file 5 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 5. Change in clinical and biological parameters between day 0 and week 6 for FMT and sham treatment groups.
Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease.
Background & Aims Treatment with immunosuppressive thiopurines such as azathioprine is associated with an increased risk of leukemogenesis. We assessed the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndromes, in a large cohort of patients with inflammatory bowel disease (IBD) in France. Methods We performed a prospective observational study of 19,486 patients with IBD enrolled in the Cancers Et Surrisque Associe aux Maladies inflammatoires intestinales En France (CESAME) study from May 2004 through June 2005; patients were followed through December 31, 2007. The incidence of myeloid disorders in the general population, which was used for reference, was de…
Incidence, Presentation, and Prognosis of Small Bowel Adenocarcinoma in Patients with Small Bowel Crohn's Disease: A Prospective Observational Study.
International audience; BACKGROUND:: Patients with Crohn's disease (CD) of the colon are at risk for colorectal cancer and should be screened for dysplasia and cancer of the colon. Small bowel adenocarcinoma (SBA) is a complication of small bowel CD and carries a poor prognosis. However, there is no screening test for SBA in patients with small bowel CD. The aim of this study was to assess the risk and incidence of SBA in a large prospective cohort of patients with small bowel CD and to compare it with the risk of colorectal cancer in patients with CD involving the colon, recruited in the same cohort. METHODS:: In a nationwide French cohort, 11,759 patients with CD were enrolled by 680 gast…
Additional file 4 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 4. Characteristics of patients at selection (before starting corticosteroids.
Additional file 1 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 1: Study design.
Additional file 8 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 8. Abundance of taxa at the genus/species level during the follow-up period in patients with FMT success (A) and FMT failure (B). Proportion of different OTU from donors in patients with FMT success and FMT failure (C). Only taxa representing > 0.1% of the microbiota were taken into account in the analysis.
Additional file 7 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 7. Principal coordinate analysis of Bray–Curtis distance in patients with FMT failure (A) or FMT sucess (B). Each PCoA plot represent the samples from a single patient across the different time points. PC1, PC2 and PC3 represent the top three principal coordinates that captured most of the diversity. The fraction of diversity captured by the coordinate is given as a percentage.
Additional file 3 of Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study
Additional file 3. Raw sequence data.